Therapeutic advances in Huntington’s disease

References

• A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Group. Cell. 1993;72(6):971–983.
   PubMed Web of Science ®Google Scholar
• Legleiter J, Mitchell E, Lotz GP, et al. Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo. J Biol Chem. 2010;285(19):14777–14790.
   PubMed Web of Science ®Google Scholar
• Cha J-HJ. Transcriptional signatures in Huntington’s disease. Prog Neurobiol. 2007;83(4):228–248.
   PubMed Web of Science ®Google Scholar
• Heng MY, Detloff PJ, Wang PL, et al. In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J Neurosci. 2009;29(10):3200–3205.
   PubMed Web of Science ®Google Scholar
• Browne SE, Bowling AC, MacGarvey U, et al. Oxidative damage and metabolic dysfunction in Huntington’s disease: selective vulnerability of the basal ganglia. Ann Neurol. 1997;41(5):646–653.
   PubMed Web of Science ®Google Scholar
• Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington’s disease. Prog Neurobiol. 2007;81(5–6):294–330.
   PubMed Web of Science ®Google Scholar
• Smith GA, Rocha EM, McLean JR, et al. Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington’s disease. Hum Mol Genet. 2014;23(17):4510–4527.
   PubMed Web of Science ®Google Scholar
• Cattaneo E, Rigamonti D, Goffredo D, et al. Loss of normal huntingtin function: new developments in Huntington’s disease research. Trends Neurosci. 2001;24(3):182–188.
   PubMed Web of Science ®Google Scholar
• Nithianantharajah J, Hannan AJ. Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington’s disease. Neuroscience. 2013;251:66–74.
   PubMed Web of Science ®Google Scholar
• Wexler NS, Lorimer J, Porter J, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington’s disease age of onset. Proc Natl Acad Sci U S A. 2004;101(10):3498–3503.
   PubMed Web of Science ®Google Scholar
• Sanberg PR, Fibiger HC, Mark RF. Body weight and dietary factors in Huntington’s disease patients compared with matched controls. Med J Aust. 1981;1(8):407–409.
   PubMed Web of Science ®Google Scholar
• Kirkwood SC, Su JL, Conneally P, et al. Progression of symptoms in the early and middle stages of Huntington disease. Arch Neurol. 2001;58(2):273–278.
   PubMedGoogle Scholar
• Snowden JS, Craufurd D, Griffiths HL, et al. Awareness of involuntary movements in Huntington disease. Arch Neurol. 1998;55(6):801–805.
   PubMedGoogle Scholar
• Sitek EJ, Soltan W, Wieczorek D, et al. Self-awareness of memory function in Parkinson’s disease in relation to mood and symptom severity. Aging Ment Health. 2011;15(2):150–156.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Roos RAC. Chorea associated with Huntington’s disease: to treat or not to treat? Mov Disord. 2014;29(11):1414–1418.
   PubMed Web of Science ®Google Scholar
• Ross CA, Pantelyat A, Kogan J, et al. Determinants of functional disability in Huntington’s disease: role of cognitive and motor dysfunction. Mov Disord. 2014;29(11):1351–1358.
   PubMed Web of Science ®Google Scholar
• Scherman D, Jaudon P, Henry JP. Characterization of the monoamine carrier of chromaffin granule membrane by binding of [2-3H]dihydrotetrabenazine. Proc Natl Acad Sci U S A. 1983;80(2):584–588.
   PubMed Web of Science ®Google Scholar
• Pettibone DJ, Pflueger AB, Totaro JA. Tetrabenazine-induced depletion of brain monoamines: mechanism by which desmethylimipramine protects cortical norepinephrine. Eur J Pharmacol. 1984;102(3–4):431–436.
   PubMed Web of Science ®Google Scholar
• Darchen F, Masuo Y, Vial M, et al. Quantitative autoradiography of the rat brain vesicular monoamine transporter using the binding of [3H]dihydrotetrabenazine and 7-amino-8-[125I]iodoketanserin. Neuroscience. 1989;33(2):341–349.
   PubMed Web of Science ®Google Scholar
• Pearson SJ, Reynolds GP. Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington’s disease. Neuropharmacology. 1988;27(7):717–719.
   PubMed Web of Science ®Google Scholar
• Lane JD, Smith JE, Shea PA, et al. Neurochemical changes following the administration of depleters of biogenic monoamines. Life Sci. 1976;19(11):1663–1667.
   PubMed Web of Science ®Google Scholar
• Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66(3):366–372.
   PubMed Web of Science ®Google Scholar
• Frank S, Ondo W, Fahn S, et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol. 2008;31(3):127–133.
   PubMed Web of Science ®Google Scholar
• Paleacu D. Tetrabenazine in the treatment of Huntington’s disease. Neuropsychiatr Dis Treat. 2007;3(5):545–551.
   PubMedGoogle Scholar
• Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997;48(2):358–362.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol. 1982;11(1):41–47.
   PubMed Web of Science ®Google Scholar
• Kingston D. Tetrabenazine for involuntary movement disorders. Med J Aust. 1979;1(13):628–630.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Tintner R, Thomas M, et al. Tetrabenazine treatment for Huntington’s disease-associated chorea. Clin Neuropharmacol. 2002;25(6):300–302.
   PubMed Web of Science ®Google Scholar
• Paleacu D, Giladi N, Moore O, et al. Tetrabenazine treatment in movement disorders. Clin Neuropharmacol. 2004;27(5):230–233.
   PubMed Web of Science ®Google Scholar
• LeWitt PA. Tardive dyskinesia caused by tetrabenazine. Clin Neuropharmacol. 2013;36(3):92–93.
   PubMed Web of Science ®Google Scholar
• Smith JM, Baldessarini RJ. Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry. 1980;37(12):1368–1373.
   PubMed Web of Science ®Google Scholar
• Guay DR. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother. 2010;8(4):331–373.
   PubMed Web of Science ®Google Scholar
• Burgunder JM, Guttman M, Perlman S, et al. An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington’s disease. PLoS Curr. 2011;3:RRN1260.
   PubMedGoogle Scholar
• Dallocchio C, Buffa C, Tinelli C, et al. Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol. 1999;19(1):101–103.
   PubMed Web of Science ®Google Scholar
• Orth M, Handley OJ, Schwenke C, et al. Observing Huntington’s disease: the European Huntington’s disease network’s registry. PLoS Curr. 2010;2:RRN1184.
   PubMedGoogle Scholar
• Deroover J, Baro F, Bourguignon RP, et al. Tiapride versus placebo: a double-blind comparative study in the management of Huntington’s chorea. Curr Med Res Opin. 1984;9(5):329–338.
   PubMed Web of Science ®Google Scholar
• Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington’s disease: an open label study. Clin Neuropharmacol. 2002;25(5):263–265.
   PubMed Web of Science ®Google Scholar
• Bonelli RM, Niederwieser G, Tribl GG, et al. High-dose olanzapine in Huntington’s disease. Int Clin Psychopharmacol. 2002;17(2):91–93.
   PubMed Web of Science ®Google Scholar
• Paleacu D, Anca M, Giladi N. Olanzapine in Huntington’s disease. Acta Neurol Scand. 2002;105(6):441–444.
   PubMed Web of Science ®Google Scholar
• Squitieri F, Cannella M, Porcellini A, et al. Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14(1):69–72.
   PubMedGoogle Scholar
• Dipple HC. The use of olanzapine for movement disorder in Huntington’s disease: a first case report. J Neurol Neurosurg Psychiatry. 1999;67(1):123–124.
   PubMed Web of Science ®Google Scholar
• Madhusoodanan S, Brecher M, Brenner R, et al. Risperidone in the treatment of elderly patients with psychotic disorders. Am J Geriatr Psychiatry. 1999;7(2):132–138.
   PubMed Web of Science ®Google Scholar
• Ciammola A, Sassone J, Colciago C, et al. Aripiprazole in the treatment of Huntington’s disease: a case series. Neuropsychiatr Dis Treat. 2009;5:1–4.
   PubMed Web of Science ®Google Scholar
• Lin WC, Chou YH. Aripiprazole effects on psychosis and chorea in a patient with Huntington’s disease. Am J Psychiatry. 2008;165(9):1207–1208.
   PubMed Web of Science ®Google Scholar
• Brusa L, Orlacchio A, Moschella V, et al. Treatment of the symptoms of Huntington’s disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord. 2009;24(1):126–129.
   PubMed Web of Science ®Google Scholar
• Bonelli RM, Niederwieser G. Quetiapine in Huntington’s disease: a first case report. J Neurol. 2002;249(8):1114–1115.
   PubMed Web of Science ®Google Scholar
• van Vugt JP, Siesling S, Vergeer M, et al. Clozapine versus placebo in Huntington’s disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry. 1997;63(1):35–39.
   PubMed Web of Science ®Google Scholar
• Mestre T, Ferreira J, Coelho MM, et al. Therapeutic interventions for symptomatic treatment in Huntington’s disease. Cochrane Database Syst Rev. 2009;3:CD006456.
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Miyasaki JM. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012;79(6):597–603.
   PubMed Web of Science ®Google Scholar
• Bonelli RM, Wenning GK. Pharmacological management of Huntington’s disease: an evidence-based review. Curr Pharm Des. 2006;12(21):2701–2720.
   PubMed Web of Science ®Google Scholar
• O’Suilleabhain P, Dewey RB Jr. A randomized trial of amantadine in Huntington disease. Arch Neurol. 2003;60(7):996–998.
   PubMed Web of Science ®Google Scholar
• Heckmann JM, Legg P, Sklar D, et al. IV amantadine improves chorea in Huntington’s disease: an acute randomized, controlled study. Neurology. 2004;63(3):597–598; author reply −8.
   PubMed Web of Science ®Google Scholar
• Verhagen Metman L, Morris MJ, Farmer C, et al. Huntington’s disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology. 2002;59(5):694–699.
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Miyasaki JM. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012;79(6):597–603.
   PubMed Web of Science ®Google Scholar
• Landwehrmeyer GB, Dubois B, de Yebenes JG, et al. Riluzole in Huntington’s disease: a 3-year, randomized controlled study. Ann Neurol. 2007;62(3):262–272.
   PubMed Web of Science ®Google Scholar
• Huntington Study Group. Dosage effects of riluzole in Huntington’s disease: a multicenter placebo-controlled study. Neurology. 2003;61(11):1551–1556.
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis/riluzole study group II. Lancet. 1996;347(9013):1425–1431.
   PubMed Web of Science ®Google Scholar
• Vaddadi KS, Soosai E, Chiu E, et al. A randomised, placebo-controlled, double blind study of treatment of Huntington’s disease with unsaturated fatty acids. Neuroreport. 2002;13(1):29–33.
   PubMed Web of Science ®Google Scholar
• Mestre T, Ferreira J, Coelho MM, et al. Therapeutic interventions for disease progression in Huntington’s disease. Cochrane Database Syst Rev. 2009;3:CD006455.
   PubMed Web of Science ®Google Scholar
• Curtis A, Mitchell I, Patel S, et al. A pilot study using nabilone for symptomatic treatment in Huntington’s disease. Mov Disord. 2009;24(15):2254–2259.
   PubMed Web of Science ®Google Scholar
• Gatto EM, Uribe Roca C, Raina G, et al. Vascular hemichorea/hemiballism and topiramate. Mov Disord. 2004;19(7):836–838.
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Sullivan KL, Hauser RA, et al. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington’s disease. Mov Disord. 2006;21(11):1998–2001.
   PubMed Web of Science ®Google Scholar
• Puri BK, Leavitt BR, Hayden MR, et al. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology. 2005;65(2):286–292.
   PubMed Web of Science ®Google Scholar
• Huntington Study Group TREND-HD Investigators. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol. 2008;65(12):1582–1589.
   PubMedGoogle Scholar
• Huntington Study Group. Minocycline safety and tolerability in Huntington disease. Neurology. 2004;63(3):547–549.
   PubMed Web of Science ®Google Scholar
• Mateo D, Gimenez-Roldan S. [The effect of piracetam on involuntary movements in Huntington’s disease. A double-blind, placebo-controlled study]. Neurologia. 1996;11(1):16–19.
   PubMedGoogle Scholar
• Hersch SM, Gevorkian S, Marder K, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2ʹdG. Neurology. 2006;66(2):250–252.
   PubMed Web of Science ®Google Scholar
• A randomized, placebo-controlled trial of coenzyme Q10. and remacemide in Huntington’s disease. Neurology. 2001;57(3):397–404.
   PubMed Web of Science ®Google Scholar
• Stocchi F, Carta A, Berardelli A, et al. Effects of terguride in patients with Huntington’s disease. Clin Neuropharmacol. 1989;12(5):435–439.
   PubMed Web of Science ®Google Scholar
• Yero T, Rey JA. Tetrabenazine (xenazine), an FDA-approved treatment option for Huntington’s disease-related chorea. P T. 2008;33(12):690–694.
   PubMedGoogle Scholar
• Frank S. Treatment of Huntington’s disease. Neurotherapeutics. 2014;11(1):153–160.
   PubMed Web of Science ®Google Scholar
• Gonzalez V, Cif L, Biolsi B, et al. Deep brain stimulation for Huntington’s disease: long-term results of a prospective open-label study. J Neurosurg. 2014;121(1):114–122.
   PubMed Web of Science ®Google Scholar
• Wojtecki L, Groiss SJ, Ferrea S, et al. A prospective pilot trial for pallidal deep brain stimulation in Huntington’s disease. Front Neurol. 2015;6:177.
   PubMed Web of Science ®Google Scholar
• Reilmann R. Pharmacological treatment of chorea in Huntington’s disease-good clinical practice versus evidence-based guideline. Mov Disord. 2013;28(8):1030–1033.
   PubMed Web of Science ®Google Scholar
• Bonelli RM, Niederwieser G, Diez J, et al. Pramipexole ameliorates neurologic and psychiatric symptoms in a Westphal variant of Huntington’s disease. Clin Neuropharmacol. 2002;25(1):58–60.
   PubMed Web of Science ®Google Scholar
• Low PA, Allsop JL. Huntington’s chorea–the rigid form (Westphal variant) treated with l-DOPA: a case report. Proc Aust Assoc Neurol. 1973;10:45–46.
   PubMedGoogle Scholar
• Low PA, Allsop JL, Halmagyi GM. Huntington’s chorea: the rigid form (Westphal variant) treated with levodopa. Med J Aust. 1974;1(11):393–394.
   PubMed Web of Science ®Google Scholar
• Racette BA, Perlmutter JS. Levodopa responsive parkinsonism in an adult with Huntington’s disease. J Neurol Neurosurg Psychiatry. 1998;65(4):577–579.
   PubMed Web of Science ®Google Scholar
• Carella F, Scaioli V, Ciano C, et al. Adult onset myoclonic Huntington’s disease. Mov Disord. 1993;8(2):201–205.
   PubMed Web of Science ®Google Scholar
• Anderson KE, Marder KS. An overview of psychiatric symptoms in Huntington’s disease. Curr Psychiatry Rep. 2001;3(5):379–388.
   PubMedGoogle Scholar
• Ho AK, Gilbert AS, Mason SL, et al. Health-related quality of life in Huntington’s disease: which factors matter most? Mov Disord. 2009;24(4):574–578.
   PubMed Web of Science ®Google Scholar
• Groves M, van Duijn E, Anderson K, et al. An international survey-based algorithm for the pharmacologic treatment of irritability in Huntington’s disease. PLoS Curr. 2011;3:RRN1259.
   PubMedGoogle Scholar
• Hassler F, Reis O. Pharmacotherapy of disruptive behavior in mentally retarded subjects: a review of the current literature. Dev Disabil Res Rev. 2010;16(3):265–272.
   PubMed Web of Science ®Google Scholar
• Anderson K, Craufurd D, Edmondson MC, et al. An international survey-based algorithm for the pharmacologic treatment of obsessive-compulsive behaviors in Huntington’s disease. PLoS Curr. 2011;3:RRN1261.
   PubMedGoogle Scholar
• Ranen NG, Peyser CE, Folstein SE. ECT as a treatment for depression in Huntington’s disease. J Neuropsychiatry Clin Neurosci. 1994;6(2):154–159.
   PubMed Web of Science ®Google Scholar
• van Duijn E, Roos RA, Smarius LJ, et al. [Electroconvulsive therapy in patients with Huntington’s disease and depression]. Ned Tijdschr Geneeskd. 2005;149(39):2141–2144.
   PubMedGoogle Scholar
• Gliatto MF, Rai AK. Evaluation and treatment of patients with suicidal ideation. Am Fam Physician. 1999;59(6):1500–1506.
   PubMed Web of Science ®Google Scholar
• Foerde K, Braun EK, Shohamy D. A trade-off between feedback-based learning and episodic memory for feedback events: evidence from Parkinson’s disease. Neurodegener Dis. 2013;11(2):93–101.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Friedman JH, Grace J, et al. Donepezil for Huntington’s disease. Mov Disord. 2000;15(1):173–176.
   PubMed Web of Science ®Google Scholar
• Rot U, Kobal J, Sever A, et al. Rivastigmine in the treatment of Huntington’s disease. Eur J Neurol. 2002;9(6):689–690.
   PubMed Web of Science ®Google Scholar
• Petrikis P, Andreou C, Piachas A, et al. Treatment of Huntington’s disease with galantamine. Int Clin Psychopharmacol. 2004;19(1):49–50.
   PubMed Web of Science ®Google Scholar
• de Tommaso M, Specchio N, Sciruicchio V, et al. Effects of rivastigmine on motor and cognitive impairment in Huntington’s disease. Mov Disord. 2004;19(12):1516–1518.
   PubMed Web of Science ®Google Scholar
• Cubo E, Shannon KM, Tracy D, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology. 2006;67(7):1268–1271.
   PubMed Web of Science ®Google Scholar
• Blackwell AD, Paterson NS, Barker RA, et al. The effects of modafinil on mood and cognition in Huntington’s disease. Psychopharmacology (Berl). 2008;199(1):29–36.
   PubMed Web of Science ®Google Scholar
• Andrews SC, Dominguez JF, Mercieca EC, et al. Cognitive interventions to enhance neural compensation in Huntington’s disease. Neurodegener Dis Manag. 2015;5(2):155–164.
   PubMedGoogle Scholar
• Thompson JA, Cruickshank TM, Penailillo LE, et al. The effects of multidisciplinary rehabilitation in patients with early-to-middle-stage Huntington’s disease: a pilot study. Eur J Neurol. 2013;20(9):1325–1329.
   PubMed Web of Science ®Google Scholar
• Zinzi P, Salmaso D, De Grandis R, et al. Effects of an intensive rehabilitation programme on patients with Huntington’s disease: a pilot study. Clin Rehabil. 2007;21(7):603–613.
   PubMed Web of Science ®Google Scholar
• Leng TR, Woodward MJ, Stokes MJ, et al. Effects of multisensory stimulation in people with Huntington’s disease: a randomized controlled pilot study. Clin Rehabil. 2003;17(1):30–41.
   PubMed Web of Science ®Google Scholar
• Mo C, Hannan AJ, Renoir T. Environmental factors as modulators of neurodegeneration: insights from gene-environment interactions in Huntington’s disease. Neurosci Biobehav Rev. 2015;52:178–192.
   PubMed Web of Science ®Google Scholar
• Bohlen S, Ekwall C, Hellstrom K, et al. Physical therapy in Huntington’s disease–toward objective assessments? Eur J Neurol. 2013;20(2):389–393.
   PubMed Web of Science ®Google Scholar
• Schilling G, Savonenko AV, Coonfield ML, et al. Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice. Exp Neurol. 2004;187(1):137–149.
   PubMed Web of Science ®Google Scholar
• Lopez-Sendon JL, Royuela A, Trigo P, et al. What is the impact of education on Huntington’s disease? Mov Disord. 2011;26(8):1489–1495.
   PubMed Web of Science ®Google Scholar
• Trembath MK, Horton ZA, Tippett L, et al. A retrospective study of the impact of lifestyle on age at onset of Huntington disease. Mov Disord. 2010;25(10):1444–1450.
   PubMed Web of Science ®Google Scholar
• Huntington Study Group HART Investigators. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington’s disease. Mov Disord. 2013;28(10):1407–1415.
   PubMed Web of Science ®Google Scholar
• de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. Pridopidine for the treatment of motor function in patients with Huntington’s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011;10(12):1049–1057.
   PubMed Web of Science ®Google Scholar
• Sampaio C, Borowsky B, Reilmann R. Clinical trials in Huntington’s disease: interventions in early clinical development and newer methodological approaches. Mov Disord. 2014;29(11):1419–1428.
   PubMed Web of Science ®Google Scholar
• Reilmann R, Rouzade-Dominguez ML, Saft C, et al. A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington’s disease. Mov Disord. 2015;30(3):427–431.
   PubMed Web of Science ®Google Scholar
• Chappie T, Humphrey J, Menniti F, et al. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape. Curr Opin Drug Discov Devel. 2009;12(4):458–467.
   PubMedGoogle Scholar
• Starr PA, Kang GA, Heath S, et al. Pallidal neuronal discharge in Huntington’s disease: support for selective loss of striatal cells originating the indirect pathway. Exp Neurol. 2008;211(1):227–233.
   PubMed Web of Science ®Google Scholar
• Tang JKH, Moro E, Lozano AM, et al. Firing rates of pallidal neurons are similar in Huntington’s and Parkinson’s disease patients. Exp Brain Res. 2005;166(2):230–236.
   PubMed Web of Science ®Google Scholar
• Biolsi B, Cif L, Fertit HE, et al. Long-term follow-up of Huntington disease treated by bilateral deep brain stimulation of the internal globus pallidus. J Neurosurg. 2008;109(1):130–132.
   PubMed Web of Science ®Google Scholar
• Cislaghi G, Capiluppi E, Saleh C, et al. Bilateral globus pallidus stimulation in Westphal variant of Huntington disease. Neuromodulation. 2014;17(5):502–505.
   PubMed Web of Science ®Google Scholar
• Fasano A, Mazzone P, Piano C, et al. GPi-DBS in Huntington’s disease: results on motor function and cognition in a 72-year-old case. Mov Disord. 2008;23(9):1289–1292.
   PubMed Web of Science ®Google Scholar
• Garcia-Ruiz PJ, Ayerbe J, del Val J, et al. Deep brain stimulation in disabling involuntary vocalization associated with Huntington’s disease. Parkinsonism Relat Disord. 2012;18(6):803–804.
   PubMed Web of Science ®Google Scholar
• Gonzalez V, Cif L, Biolsi B, et al. Deep brain stimulation for Huntington’s disease: long-term results of a prospective open-label study. J Neurosurg. 2014;121(1):114–122.
   PubMed Web of Science ®Google Scholar
• Gruber D, Kuhn AA, Schoenecker T, et al. Quadruple deep brain stimulation in Huntington’s disease, targeting pallidum and subthalamic nucleus: case report and review of the literature. J Neural Transm (Vienna). 2014;121(10):1303–1312.
   PubMed Web of Science ®Google Scholar
• Hebb MO, Garcia R, Gaudet P, et al. Bilateral stimulation of the globus pallidus internus to treat choreathetosis in Huntington’s disease: technical case report. Neurosurgery. 2006;58(2):E383; discussion E.
   PubMedGoogle Scholar
• Huys D, Bartsch C, Poppe P, et al. Management and outcome of pallidal deep brain stimulation in severe Huntington’s disease. Fortschr Neurol Psychiatr. 2013;81(4):202–205.
   PubMed Web of Science ®Google Scholar
• Kang GA, Heath S, Rothlind J, et al. Long-term follow-up of pallidal deep brain stimulation in two cases of Huntington’s disease. J Neurol Neurosurg Psychiatry. 2011;82(3):272–277.
   PubMed Web of Science ®Google Scholar
• Moro E, Lang AE, Strafella AP, et al. Bilateral globus pallidus stimulation for Huntington’s disease. Ann Neurol. 2004;56(2):290–294.
   PubMed Web of Science ®Google Scholar
• Spielberger S, Hotter A, Wolf E, et al. Deep brain stimulation in Huntington’s disease: a 4-year follow-up case report. Mov Disord. 2012;27(6):806-7;author reply 7-8.
   PubMed Web of Science ®Google Scholar
• Velez-Lago FM, Thompson A, Oyama G, et al. Differential and better response to deep brain stimulation of chorea compared to dystonia in Huntington’s disease. Stereotact Funct Neurosurg. 2013;91(2):129–133.
   PubMed Web of Science ®Google Scholar
• Lopez-Sendon Moreno JL, Garcia-Caldentey J, Regidor I, et al. A 5-year follow-up of deep brain stimulation in Huntington’s disease. Parkinsonism Relat Disord. 2014;20(2):260–261.
   PubMed Web of Science ®Google Scholar
• Zeef DH, Vlamings R, Lim LW, et al. Motor and non-motor behaviour in experimental Huntington’s disease. Behav Brain Res. 2012;226(2):435–439.
   PubMed Web of Science ®Google Scholar
• Smith KM, Spindler MA. Uncommon applications of deep brain stimulation in hyperkinetic movement disorders. Tremor Other Hyperkinet Mov (N Y). 2015;5:278.
   PubMedGoogle Scholar
• Gibrat C, Cicchetti F. Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(2):380–389.
   PubMed Web of Science ®Google Scholar
• Borrell-Pages M, Canals JM, Cordelieres FP, et al. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest. 2006;116(5):1410–1424.
   PubMed Web of Science ®Google Scholar
• Besouw M, Masereeuw R, van den Heuvel L, et al. Cysteamine: an old drug with new potential. Drug Discov Today. 2013;18(15–16):785–792.
   PubMed Web of Science ®Google Scholar
• Smith MR, Syed A, Lukacsovich T, et al. A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington’s disease. Hum Mol Genet. 2014;23(11):2995–3007.
   PubMed Web of Science ®Google Scholar
• Huntington Study Group Reach2HD Investigators. Safety, tolerability, and efficacy of PBT2 in Huntington’s disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015;14(1):39–47.
   PubMed Web of Science ®Google Scholar
• Bjorkqvist M, Wild EJ, Thiele J, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease. J Exp Med. 2008;205(8):1869–1877.
   PubMed Web of Science ®Google Scholar
• Sagredo O, Pazos MR, Valdeolivas S, et al. Cannabinoids: novel medicines for the treatment of Huntington’s disease. Recent Pat CNS Drug Discov. 2012;7(1):41–48.
   PubMedGoogle Scholar
• Lopez-Sendon Moreno JL, Garcia Caldentey J, Trigo Cubillo P, et al. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease. J Neurol. 2016. [Epub ahead of print].
   PubMedGoogle Scholar
• Bruck W, Pfortner R, Pham T, et al. Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012;124(3):411–424.
   PubMed Web of Science ®Google Scholar
• Ross CA, Akimov SS. Human-induced pluripotent stem cells: potential for neurodegenerative diseases. Hum Mol Genet. 2014;23(R1):R17–R26.
   PubMed Web of Science ®Google Scholar
• Smith DK, He M, Zhang CL, et al. The therapeutic potential of cell identity reprogramming for the treatment of aging-related neurodegenerative disorders. Prog Neurobiol. 2016. [Epub ahead of print].
   PubMedGoogle Scholar
• Wild EJ, Tabrizi SJ. Targets for future clinical trials in Huntington’s disease: what’s in the pipeline? Mov Disord. 2014;29(11):1434–1445.
   PubMed Web of Science ®Google Scholar
• Harper SQ, Staber PD, He X, et al. RNA interference improves motor and neuropathological abnormalities in a Huntington’s disease mouse model. Proc Natl Acad Sci U S A. 2005;102(16):5820–5825.
   PubMed Web of Science ®Google Scholar
• Stanek LM, Sardi SP, Mastis B, et al. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington’s disease. Hum Gene Ther. 2014;25(5):461–474.
   PubMed Web of Science ®Google Scholar
• Carroll JB, Warby SC, Southwell AL, et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. Mol Ther. 2011;19(12):2178–2185.
   PubMed Web of Science ®Google Scholar
• Nasir J, Floresco SB, O’Kusky JR, et al. Targeted disruption of the Huntington’s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell. 1995;81(5):811–823.
   PubMed Web of Science ®Google Scholar
• Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12(5):435–442.
   PubMed Web of Science ®Google Scholar
• Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy. Neurology. 2016;86(10):890–897.
   PubMed Web of Science ®Google Scholar
• Banez-Coronel M, Ayhan F, Tarabochia AD, et al. RAN translation in Huntington disease. Neuron. 2015;88(4):667–677.
   PubMed Web of Science ®Google Scholar